- Proven superior LDL-C lowering efficacy and safety compared to statin monotherapy.

- Achieves over 50% LDL-C reduction even at low dose (10/2.5 mg) – enabling personalized treatment.

- Supported by RACING study involving 3,780 patients, emerging as a new standard in dyslipidemia management.

‍

(Jakarta, October 6^th, 2025)

‍

Daewoong Pharmaceutical is accelerating its entry into the Indonesian market by presenting its dyslipidemia treatment at Indonesia’s leading cardiology congress, the Annual Scientific Meeting of the Indonesian Heart Association (ASMIHA) 2025.

‍

Now in its 34th year, ASMIHA is the largest scientific event in Indonesia dedicated to cardiovascular medicine. The congress, held from October 1–4, 2025, at the InterContinental Pondok Indah Hotel in Jakarta, gathered cardiologists, healthcare professionals, and researchers to explore the future of cardiovascular disease treatment.

‍

According to data released this year by the U.S. National Institutes of Health (NIH), about 40 million adults in Indonesia suffer from elevated LDL-cholesterol (LDL-C) levels, increasing their risk of cardiovascular disease. Many remain untreated, which is cited as a major factor behind the rising mortality rate from cardiovascular disease. Improving treatment accessibility and awareness is therefore an urgent priority.

‍

This challenge is further highlighted by international research. The INTERASPIRE study (European Heart Journal, 2024) reported that in Indonesia, only 16.6% of coronary artery disease patients achieved the recommended LDL-C target of <70 mg/dL, while overall guideline adherence remained extremely low. The majority of patients failed to control blood pressure, showed high prevalence of diabetes and obesity, and had limited participation in cardiac rehabilitation programs.

‍

Baik In Hyun, Director of Daewoong Pharmaceutical Indonesia, stated, “Cardiovascular disease is the number one cause of death in Indonesia, yet many patients still fail to lower their LDL-cholesterol effectively.” He added, “Addressing these unmet medical needs is one of our key missions at Daewoong Indonesia, as we strive to improve the quality of life for the Indonesian people.”

Dual-Inhibition Based Daewoong’s Dyslipidemia Therapy Presents a New Standard in the “Lower is Better” Paradigm

At ASMIHA, Daewoong hosted a symposium under the theme “Evolving LDL-Cholesterol Management and Dual-Inhibition Therapy Strategies for High-Risk Cardiovascular Patients.”

‍

Dr. Ade Meidian Ambari, President of the Indonesian Heart Association, explained that in the past, LDL-cholesterol goals for high-risk cardiovascular patients were set at <100 mg/dL or <70 mg/dL. However, even at these levels, many patients remained at high risk of major cardiovascular events such as myocardial infarction and stroke.

‍

He emphasized that the 2021 ESC/EAS guidelines further lowered the target for very high-risk patients to <55 mg/dL, clearly reinforcing the principle that “the lower, the better”. Dr. Ade added:

‍

“In this evolving global treatment landscape, monotherapy alone is insufficient. A dual-inhibition approach with rosuvastatin and ezetimibe provides the optimal pathway to achieve LDL-C goals and sustain long-term treatment.”

‍

Dual-inhibition therapy combines rosuvastatin, which suppresses cholesterol synthesis in the liver, with ezetimibe, which inhibits cholesterol absorption in the small intestine. Together, they allow patients to achieve target levels more powerfully and safely than with monotherapy.

‍

Daewoong’s Dyslipidemia Therapy: Stronger LDL-C Reduction, Personalized Options, and Clinical Evidence

Daewoong’s dyslipidemia therapy demonstrates significantly stronger LDL-C lowering efficacy than existing treatments. It has proven superior efficacy and a lower risk of side effects compared to statin monotherapy, achieving over 50% LDL-C reduction even at a low dose of 10/2.5 mg, fully aligned with the “Lower is Better” paradigm.

‍

In addition, Daewoong’s dyslipidemia therapy offers three dosage options (10/5 mg, 10/10 mg, 10/20 mg)—including Indonesia’s first 10/5 mg low-dose fixed combination—allowing personalized treatment tailored to patient needs. Rosuvastatin, as the only statin with clinical evidence of delaying atherosclerosis progression, further strengthens the potential of Daewoong’s dyslipidemia therapy to become a new standard in dyslipidemia treatment.

‍

Dr. Ade Meidian Ambari commented, “For very high-risk patients, a dual-inhibition strategy that suppresses both synthesis and absorption is the most effective way to achieve LDL-C goals. Daewoong’s dyslipidemia therapy enables this approach, offering significant improvements in treatment outcomes for patients.”

‍

Large-Scale Clinical Evidence: The RACING Study At the symposium, Daewoong also presented data comparing statin monotherapy to combination therapy.

Professor JeeHoon Kang of Seoul National University Hospital presented the findings of the RACING study, which enrolled 3,780 patients with atherosclerotic cardiovascular disease (ASCVD) in Korea. The study showed that a fixed-dose combination of rosuvastatin and ezetimibe—the same dual-inhibition mechanism as Daewoong’s dyslipidemia therapy—achieved a significantly higher one-year LDL-C goal attainment rate compared to high-intensity statin monotherapy (73% vs. 55%), with lower treatment discontinuation rates, making it more favorable for long-term adherence (The Lancet, 2022).

‍

Professor JeeHoon Kang commented, “In reality, most patients still fail to achieve treatment targets. Daewoong’s dyslipidemia therapy represents a meaningful alternative that has arrived at the right time.” He added, “By utilizing dual-inhibition, it reduces side effect burden while improving efficacy, which is highly impressive. The 2025 guidelines will set even stricter LDL-C goals, and Daewoong’s dyslipidemia therapy is well-positioned to become the new benchmark for treatment.”

‍

Market Entry Strategy in Indonesia Starting with its participation in ASMIHA, Daewoong Pharmaceutical is preparing the official launch of its dyslipidemia therapy in Indonesia in November 2025. Under the vision “Smarter Strategy for Uncompromised LDL-C Control”, Daewoong aims to provide new therapeutic options for Indonesian physicians and patients, while ultimately positioning its dyslipidemia therapy as a new standard for dyslipidemia management across ASEAN.

‍

Professor JeeHoon Kang stated, “Daewoong’s fixed-dose dyslipidemia combination therapy offers a new treatment alternative by effectively lowering LDL-cholesterol while reducing the side effect burden of high-dose statins.” He added, “This approach benefits both patients and physicians.”